A Phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

By El-Rayes Basil   Zalupski Mark   Shields Anthony   Ferris Ann   Vaishampayan Ulka   Heilbrun Lance   Venkatramanamoorthy Raghu   Adsay Volkan   Philip Philip  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 583-590

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

By Renouf Daniel  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 779-786

Springer Publishing Company

Access to resources Recommend Favorite

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

By Tsavaris Nicolas   Kosmas Christos   Skopelitis Helias   Gouveris Panagiotis   Kopteridis Petros   Loukeris Dioynissis   Sigala Frantzeska   Zorbala-Sypsa Alexandra   Felekouras Evangelos   Papalambros Efstathios  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 369-375

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study

By Richards Donald   Kuefler Paul   Becerra Carlos   Wilfong Lalan   Gersh Robert   Boehm Kristi   Zhan Feng   Asmar Lina   Myrand Scott   Hozak Rebecca   Zhao Luping   Gill John   Mullaney Brian   Obasaju Coleman   Nicol Steven  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 144-153

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib + gemcitabine of no value in pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite